← Back to Analyst Consensus 
CADL Buy
Candel Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| Sep 21, 2026 | B of A Securities | upgrade | Neutral → Buy | — | 53% |
| Aug 14, 2026 | B of A Securities | maintain | Neutral → Neutral | — | 53% |
| Aug 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 13, 2026 | Stifel | initiate | — → Buy | — | 53% |
| Apr 20, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Mar 18, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 13, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 13, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Dec 8, 2025 | Stephens & Co. | reiterate | Overweight → Overweight | $15 | 54% |
| Nov 21, 2025 | Freedom Broker | maintain | Buy → Buy | — | 60% |
| Nov 14, 2025 | Citigroup | maintain | Buy → Buy | $24 | 54% |
| Oct 28, 2025 | Stephens & Co. | initiate | — → Overweight | $15 | 54% |
| Oct 21, 2025 | LifeSci Capital | initiate | — → Outperform | $16 | 57% |
| Sep 29, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Sep 3, 2025 | B of A Securities | downgrade | Buy → Neutral | $7 | 53% |
| Apr 11, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Mar 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Feb 26, 2025 | Canaccord Genuity | maintain | Buy → Buy | $25 | 48% |
| Feb 26, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Feb 20, 2025 | Citigroup | initiate | — → Buy | $25 | 54% |
| Feb 19, 2025 | Canaccord Genuity | initiate | — → Buy | $20 | 48% |
| Feb 7, 2025 | B of A Securities | initiate | — → Buy | $15 | 53% |
| Dec 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Nov 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Nov 13, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| May 22, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| May 15, 2023 | BMO Capital | maintain | Outperform → Outperform | $3 | 53% |
| Mar 31, 2023 | Credit Suisse | maintain | — → Outperform | $7 | — |
| Dec 7, 2022 | Credit Suisse | maintain | — → Outperform | $8 | — |
| Dec 2, 2022 | HC Wainwright & Co. | initiate | — → Buy | $11 | 44% |
| Mar 31, 2022 | BMO Capital | maintain | — → Outperform | $12 | 53% |
| Nov 19, 2021 | BMO Capital | initiate | — → Outperform | $18 | 53% |
| Aug 23, 2021 | UBS | initiate | — → Buy | $9 | 54% |
| Aug 23, 2021 | Jefferies | initiate | — → Buy | $22 | 52% |
| Aug 23, 2021 | Credit Suisse | initiate | — → Outperform | $15 | — |
Price Target Trend
Apr 25, 2026 Latest: $22.11 Oct 26, 2026
EPS Estimates
+1q $-0.33
Lo: $-0.33 Hi: $-0.32
2 analysts 0y $-1.08
Lo: $-1.28 Hi: $-0.74
3 analysts +1y $-0.63
Lo: $-1.47 Hi: $0.22
2 analysts 0q $-0.31
Lo: $-0.33 Hi: $-0.29
2 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days